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Background: Glycyrrhizin (GA) and primary metabolite 18β-glycyrrhetinic acid (GRA) are pharmacologically active
components of the medicinal licorice root, and both have been shown to have antiviral and immunomodulatory
properties. Although these properties are well established, the mechanisms of action are not completely
understood. In this study, GA and GRA were tested for the ability to inhibit rotavirus replication in cell culture,
toward a long term goal of discovering natural compounds that may complement existing vaccines.
Methods: Epithelial cells were treated with GA or GRA various times pre- or post-infection and virus yields were
measured by immunofluorescent focus assay. Levels of viral proteins VP2, VP6, and NSP2 in GRA treated cells were
measured by immunoblot to determine if there was an effect of GRA treatment on the accumulation of viral
protein.
Results: GRA treatment reduced rotavirus yields by 99% when added to infected cultures post- virus adsorption,
whereas virus yields in GA treated cultures were similar to mock treated controls. Time of addition experiments
indicated that GRA-mediated replication inhibition likely occurs at a step or steps subsequent to virus entry. The
amounts of VP2, VP6 and NSP2 were substantially reduced when GRA was added to cultures up to two hours post-
entry.
Conclusions: GRA, but not GA, has significant antiviral activity against rotavirus replication in vitro, and studies to
determine whether GRA attenuates rotavirus replication in vivo are underway.
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Rotaviruses are the most prevalent cause of acute viral
gastroenteritis in children less than five years of age. Re-
cent estimates indicate 2.7 million cases occur each year
in the U.S. and 600,000 deaths occur annually worldwide
(reviewed in [1]). Available data on two attenuated vac-
cines show they both are efficacious in reducing the inci-
dence and severity of rotavirus gastroenteritis in the U.S.
and other developed countries [2–5]. Reported vaccine
efficacy is lower in developing nations where the major-
ity of deaths from rotavirus infections occur, likely due
to multiple factors including suboptimal immune
responses associated with poor nutritional status or con-
current enteric infections [4,6,7]. Methods to enhance* Correspondence: mhardy@montana.edu
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reproduction in any medium, provided the ornatural disease resistance find value in these regions if
protective immunity could be improved by complement-
ing existing vaccines with products that have antiviral or
immune adjuvant activity.
Licorice is derived from the root of the perennial herb
Glycyrrhiza spp., and in addition to its use as a sweeten-
ing agent, has been one of the more extensively used
medicinal plants [8]. Pharmacologically active compo-
nents that have been most studied include triterpene
saponins, with glycyrrhizin (GA) being present in the
highest concentration [9,10]. 18β-glycyrrhetinic acid
(GRA) is the aglycone product of GA hydrolysis
mediated in the gut by bacterial glucoronidases [11,12].
Both GA and GRA have been studied in several systems
to evaluate their immunomodulatory properties. GA has
been used in Japan for >20 years to treat chronic viral
hepatitis, and patients administered a continuous regi-
men of an intravenous formulation of GA (Strongertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 GRA and GA cytotoxicity in MA104 cells MA104 cells
were treated for six hours with the indicated concentrations of
GA or GRA. Viability was measured with the Promega CellTiterGlo
Assay according to the manufacturer’s protocol, with digitonin as
the control for 100% cytotoxicity. Red bars indicate GRA and blue
bars GA. Data shown are representative of two experiments, with
each concentration tested in triplicate in each experiment. Error bars
indicate SEM.
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provement and reduced incidence of hepatocellular car-
cinoma [13–16]. GA also has been studied in an animal
model of viral infection. Mice administered GA intraper-
itoneally survived a lethal dose of influenza virus [17].
Antibody to IFNγ abolished this protective effect, but
the mechanisms of protection in this model system re-
main unclear. While mechanisms of action in vivo are
not well understood, they likely are multi-factorial and
could be due to direct effects on virus replication, or
functions associated with modulation of inflammatory
and cell protective responses.
The initial report describing antiviral activity of GA
in vitro showed reduced replication of vesicular stoma-
titis virus (VSV), vaccinia virus (VV), herpes simplex 1
virus (HSV-1), and Newcastle Disease virus (NDV), but
not poliovirus type 1 [18]. Subsequently, GA was shown
to have antiviral activity against viruses in several fam-
ilies including flaviviruses, herpesviruses, influenza virus,
SARS coronavirus, hepatitis C virus and others
(reviewed in [19]). Suggested mechanisms of activity in
these systems include direct effects on the adsorption,
penetration and particle maturation steps of the replica-
tion cycle and in some cases, direct inactivation of virus
particles. For example, anti-influenza virus activity of
GA in cell culture was attributed to interference with
viral endocytosis, likely due to its ability to modulate
membrane fluidity [20,21], although alternative mechan-
isms recently have been proposed [22].
GRA has anti-tumorigenic, anti-ulcerative, anti-inflam-
matory, and anti-hepatotoxic activity in vitro and in vivo
[19,23]. The utility of GRA as an antiviral compound is
not as well described as GA, but there are data to suggest
GRA has immunomodulatory and cell protective activity
in vitro and in vivo. For example, in vitro, GRA induces
NFĸB-mediated nitric oxide synthase expression in
macrophages [24], and IL-8 expression in epithelial cells
[25]. Others studies also suggest potential anti-inflamma-
tory activity associated with reduced cytokine expression
and attenuation of NFĸB activation [26,27]. In vivo, pro-
tective efficacy of GRA against protozoan and bacterial
infections has been demonstrated. In a mouse model of
visceral leishmaniasis [24,28], analysis of pro-inflammatory
cytokine transcripts in isolated spleen cells from infected
animals revealed that GRA induces IFNγ, TNFα, and IL-
12, indicative of a TH1 and curative response. In a bacterial
system, GRA attenuated lung pathology associated with
Staphyloccus aureus pneumonia [29].
The relative lack of data regarding specific antiviral ac-
tivity of GRA compared to GA led us to expand on pre-
vious data showing GRA treatment reduces rotavirus
replication in cell culture [25], and include GA in our
analyses, given the wealth of data available for this com-
pound and its current availability for clinical use. Weshow that GRA treatment results in a significant reduc-
tion in rotavirus titers when added to cultures post-in-
fection. The levels of viral structural proteins VP2 and
VP6, and nonstructural protein NSP2 were reduced in
GRA treated cells, consistent with anti-rotavirus activity
of this compound.Results
GRA and GA cytotoxicity in MA104 cells
We have shown that GRA is not toxic to MA104 cells
up to the highest concentration tested of 10 μg/mL [25].
We performed an extended titration in this study and
included GA, for which cytotoxicity in these cells had
not previously been tested. MA104 cells were treated
with serial dilutions of GA or GRA, and cytotoxicity was
measured following six hours of incubation. The data
shown in Figure 1 indicate that concentrations of 10 μg/
mL and 25 μg/mL GRA showed only approximately 7%
and 15% reductions in cell viability, respectively, at this
time point. Extension of incubations past 24 hours
resulted in significant cytotoxicity (data not shown). In
contrast to GRA, GA was cytotoxic only at the highest
concentration tested of 10 mg/mL. Each compound was
used in the remainder of the experiments at a final con-
centration of 25 μg/mL.GRA reduces rotavirus infectivity while GA has no effect
A previous time course of the effects of GRA on rota-
virus replication showed an approximately 40%
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when cells were treated as few as six hours prior to in-
fection [25]. The prior experiments measured replication
at a low multiplicity of infection (0.01 pfu/cell) over a
long course of infection, and measured cell-associated
virus. The current experiments were designed to meas-
ure one round of replication at a higher multiplicity of
infection (three pfu/cell) so that we could begin to de-
cipher mechanisms of inhibition that did not include
cell-to-cell spread. To test inhibitory effects of GA and
GRA on rotavirus infectivity, each compound was added
to cells either six hours prior to RRV infection, or fol-
lowing the adsorption step. Cultures then were har-
vested six hours post-infection, and infectious virus was
titered by IFA. In contrast to previous studies using a
low multiplicity of infection, pre-treatment only did not
significantly reduce virus titers under the conditions of
these experiments (Figure 2). In contrast, GRA treat-
ment resulted in a 99% reduction in infectivity when the
compound was continuously present (pre/post) or when
added post-infection only (post). This level of reduction
in virus yields cannot be explained by simple cytotoxic
effects on the cells at the degree defined by the toxicity
assays. GA had no effect on virus yield whether the* 
* 
Figure 2 GRA reduces rotavirus yields when added
post-infection. MA104 cells were infected with rotavirus strain RRV
at a multiplicity of infection of 3 pfu/cell. 25 μg/mL GRA was added
to the cultures either six hours pre-infection and then removed for
the remaining time (pre) or was present continuously in the media
throughout the course of infection (pre/post). For post-infection
treatments, GRA was added to the cultures following the one hour
virus adsorption period and maintained in the media throughout
the infection. Total virus was harvested from cells and supernatant,
and yields of infectious virus were determined by IFA. Data shown
are representative of two experiments with triplicate samples in
each experiment. Analysis for significance was performed using a
two--tailed Student’s t test. Errors indicate SEM. *p = 0.006.compound was added pre- or post-infection, as titers did
not differ significantly from mock treated, infected con-
trols. Therefore, GA was not investigated further.
GRA does not reduce infectivity through a direct effect on
the virus particle
GRA reduced rotavirus infectivity when added to the
cultures following the adsorption step. To determine if
there was a direct effect of GRA on the virus particle,
RRV stock was mixed with 25 μg/mL GRA or DMSO
and incubated for one hour at 37°C. Virus in suspension
then was concentrated by ultracentrifugation and infect-
ivity was measured by IFA. The data shown in Figure 3A
illustrate that infectivity was not reduced when stock
virus was treated with GRA prior to inoculation, sug-
gesting that the ability of GRA to inhibit replication was
not a result of a direct detrimental effect on the virus
particle.
GRA reduces infectivity at a post-entry step
GRA was inhibitory to RRV replication only when added
to cultures post-virus adsorption. To determine whether
the reduction in titer observed when cells were treated
with GRA was a result of a block to virus entry, cells
were inoculated with RRV at a multiplicity of infection
of three pfu/cell, and virus was adsorbed for one hour at
4°C. Incubation at 4°C allows virus adsorption, but not
entry into the cells [30,31]. After the adsorption period,
cultures were incubated for one hour at 37°C to allow
virus entry, and then GRA or DMSO was added and
infections were allowed to proceed for five hours. The
results showed that infectious virus titers were reduced
by 99% when GRA was added following the 37°C incu-
bation (Figure 3B), suggesting that GRA inhibits RRV
replication at a step that is subsequent to virus entry
into the cell.
Viral protein levels are reduced in GRA treated cells
To begin to understand how GRA is inhibiting replica-
tion, the levels of viral protein in GRA treated cells were
examined. As before, RRV was adsorbed to the mono-
layer for one hour at 4°C, adsorption medium was
removed and replaced with fresh medium, and cultures
were incubated for one hour at 37°C to allow virus entry.
GRA then was added to the cultures and infections were
allowed to proceed for five hours. Lysates were prepared
and subjected to immunoblot. Figure 4A shows there
was a substantial reduction in the amount of VP2 and
VP6 in GRA treated cells. Evidence that virus replication
was occurring and measurable at this time point was
provided by detection of NSP2, the levels of which also
were significantly reduced in treated cells compared to
untreated cells. To further assess the reduction in the
amount of VP2, VP6, and NSP2 in treated cells, the
B A 
Figure 3 GRA does not inactivate the rotavirus particle and inhibits replication postentry. A) RRV stocks were incubated with 25 μg/mL
GRA or DMSO for one hour at 37°C. Virus then was concentrated by ultracentrifugation for two hours at 35,000 rpm in an SW55 rotor (Beckman)
and infectivity was measured by IFA. Data are from triplicate samples, p < 0.001. B) Trypsin-activated RRV was inoculated onto cells at a
multiplicity of infection of 3 pfu/cell and adsorbed for one hour at 4°C. Following adsorption, the medium was replaced and cultures were
incubated for one hour at 37°C to allow virus entry. 25 μg/mL GRA or DMSO was added to the culture following the 37°C incubation, and virus
titers following an additional 5 hours of infection were determined by IFA. Data were analyzed for significance with the two-tailed Student’s t
test. Error bars indicate SEM. p < 0.004.
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added two hours following the 37°C incubation. The
results indicated that the degree of reduction in VP2 was
similar to the previous experiment (Figure 4B). The
amounts of VP6 and NSP2 still were diminished. How-
ever, they were higher than those observed when GRA
was added one hour following the 37°C incubation.
While one interpretation of these results suggests
addition of GRA at later times post-adsorption may di-
minish its effects on levels of viral protein and conse-
quently virus titers, the observation that the level of VP2






















Figure 4 GRA treatment reduces the levels of VP2, VP6 and NSP2 in i
infection of 3 pfu/cell. Virus was adsorbed for one hour at 4°C, and culture
addition of GRA. Lysates were probed in immunoblots with anti-rotavirus s
GAPDH as a loading control. The lanes are triplicate samples. Bands were q
in the individual samples normalized to the averaged intensity of the GAPDTogether, the data show GRA has a profound effect on
the accumulation of rotavirus proteins in infected cells,
consistent with the observed reduction in yields of infec-
tious virus.
Discussion
The antiviral properties of two principal pharmacologically
active constituents of licorice root, GA and GRA, have
been extensively described, with by far the most data avail-
able for GA [8,23,32,33]. The mechanisms by which these
compounds are antiviral, and the steps of the virus replica-





















nfected cells. Cells were inoculated with RRV at a multiplicity of
s then were shifted to 37°C for one hour (A) or two hours (B) prior to
train SA11F antiserum to detect VP2 and VP6, anti-NSP2, or anti-
uantified by densitometry taking the averaged intensity of the bands
H loading control in each sample.
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viral activity of GA in vivo may result from induction of
cytoprotective and immunomodulatory responses rather
than effects on virus-specific functions per se, and such
mechanisms of action could in part explain its broad-
spectrum activity (reviewed in [32]. In contrast to GA,
fewer reports of in vivo activity of GRA are available.
However, when administered intravenously, GA is meta-
bolized in the liver by lysosomal β-D-glucoronidase into
3-mono-glucoronide-glycyrrhetinic acid, and then finally
by glucoronidases of intestinal bacteria into GRA, which
then can be reabsorbed [11,12,34]. Therefore, it is possible
that some of the in vivo effects of GA are due to one or
more of its metabolites, including GRA.
We have shown that GRA reduces rotavirus yields
during a single round of replication in MA104 cells
whereas GA does not. Given numerous reports of anti-
viral activity of GA in vitro, it was somewhat surprising
that GA did not effect rotavirus replication. However, in-
hibitory activity of GA may have a preference for envel-
oped viruses, consistent with potential mechanisms of
action attributed to its effects on membrane fluidity.
GRA did not directly inactivate the rotavirus particle
because yields of infectious virus were not reduced when
virus stocks were incubated with the compound prior to
inoculation onto cells. The reduction in yields of infec-
tious virus and viral protein levels when GRA was added
to cultures up to two hours post-adsorption suggests
interference with rotavirus replication occurs at a step
subsequent to virus entry. These data are consistent with
previous studies illustrating a similar effect of GA on
in vitro replication of NDV, VSV, HSV-1, and VV when
the compound was added several hours post-infection
[18]. Interestingly, the amount of VP2 present when
GRA was added two-hours post-entry was similar to the
levels observed when GRA was added one hour post-
entry, but the amounts of VP6 and NSP2 were consider-
ably higher. This observation could be explained by
effects on viral transcription, translation or degradation
of viral proteins, but how such mechanisms would ex-
plain the selective reduction are difficult to predict.
Studies to conclusively define steps at which GRA exerts
its inhibitory effect are in progress.
There are multiple mechanisms by which GRA could
reduce virus yields, including effects on specific steps of
the replication cycle or on cellular pathways that play a
role in establishment of an environment conducive to
maximum replication efficiency. For example, we have
shown that GRA induces NFĸB activation in MA104
cells [25], and more recently reported that some rota-
virus strains down-regulate NFĸB activity through the
functions of nonstructural protein NSP1 [35]. NFĸB ac-
tivity is required for induction of a robust antiviral re-
sponse, and sustained activation of NFĸB by GRA couldoverride virus-encoded mechanisms that down-regulate
its activity, resulting in reduced virus replication. Other
studies also report GRA-mediated activation of NFĸB
[24,28]. Of note, however, are reports showing GRA
inhibits NFĸB activation, and this has been interpreted
as GRA-mediated regulation of the inflammatory re-
sponse [22,26,36]. In these and other studies, the effects
of GRA on NFĸB were measured following induction of
the pathway by virus infection or by pro-inflammatory
mediators, suggesting that the effects of GRA on NFĸB
are context-dependent. Deciphering the interactions be-
tween GRA and the NFĸB signaling pathway at the mo-
lecular level will contribute to understanding how its
activity is modulated depending on the stimulus. One
possible alternative mechanism of replication inhibition
that is not mutually exclusive is provided by several
reports indicating GRA modulates PI3/Akt activity
[27,37,38]. Pharmacological inhibition of the PI3/Akt
pathway substantially reduces rotavirus yields in culture
[39]. The effects of GRA on these signaling pathways in
the context of rotavirus infection and how GRA may
modulate them currently are under investigation.
Together, the data reported here show GRA inhibits
rotavirus replication at a step or steps subsequent to
virus entry, and support antiviral activity of GRA
reported in other systems. Rotavirus infects mature
enterocytes at the villus tips in the proximal small intes-
tine and thus in vivo, the tropism is polarized epithelial
cells. Continuing studies will address whether there is a
difference either in GRA toxicity or in the levels of re-
duction in virus replication in this cell type. We have
administered GRA up to concentrations of 50 mg/kg to
mice and have not observed clinical signs that would in-
dicate toxicity (unpublished data), suggesting that inhibi-
tory levels can be achieved in vivo. We currently are
determining whether GRA-mediated replication inhib-
ition in vitro translates to attenuation of virus replication
in the mouse model of rotavirus infection.
Methods
Cells, virus, and compounds
MA104 monkey kidney epithelial cells (ATCC CRL2378)
were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM, Mediatech) supplemented with 5% fetal bovine
serum (FBS, Atlanta Biologicals). Rhesus rotavirus strain
RRV was propagated in MA104 cells and stock titers
were determined by immunofluorescent focus assay
(IFA, see below).
Glycyrrhizin (GA) and 18β-glycyrrhetinic acid (GRA)
were purchased from Sigma-Aldrich. Stock solutions
were prepared to a concentration of 100 mg/mL in
DMSO and aliquots were stored at -80°C. Stock solu-
tions were diluted to working concentrations in DMEM
without FBS.
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Cell viability under conditions of GA or GRA treatment
was measured with the CellTiter-Glo Luminescent Cell
Viability Assay (Promega) following the manufacturer’s
protocol. Controls for 100% cell viability or 100% tox-
icity consisted of cells and media alone, or treatment
with digitonin, respectively.
Immunofluorescent focus assay (IFA)
Rotavirus infectivity following various treatments was
determined by IFA as previously described [25]. Briefly,
MA104 cells were cultured to confluence in 96-well
microtiter plates. Wells were inoculated with 10-fold
dilutions of RRV stock pre-treated with 10 μg/mL
TPCK-trypsin (Worthington Biochemicals) for 30 min-
utes at 37°C. Sixteen hours post-infection, cells were
fixed for 10 minutes with 2% paraformaldehyde, and
then for 10 minutes with ice cold 100% methanol to
permeabilize membranes. Structural protein VP6 was
detected with mouse monoclonal antibody A6M [25] at
a 1:200 dilution, followed by Alexa FluorW 488-conju-
gated goat anti-mouse antibody (1:4000, Molecular
Probes). VP6-positive foci indicative of infected cells
were enumerated and titers expressed as fluorescent
focus units (FFU) per mL.
Infections, compound treatments, and culture harvest
Infections were performed as previously described [40].
MA104 cells were inoculated with trypsin-activated RRV
at a multiplicity of infection of three pfu/cell, and virus
was adsorbed to cells for one hour at 37°C. Following
the adsorption step, media was removed and replaced
with fresh media with or without compound according
to the parameters of the experiment. Six hours post-in-
fection, cells and supernatant were collected and sub-
jected to three freeze-thaw cycles. Lysates were clarified
by low speed centrifugation, and virus in the supernatant
was titered by IFA.
GA, GRA, or DMSO vehicle control was added to cul-
tures at the times indicated by each experiment. Pre-in-
fection treatments were for six hours prior to addition of
virus, and compound was not present in the media for
the remainder of the infection. For post-infection treat-
ments, compound was added following the virus adsorp-
tion or entry step and was present in the media for the
duration of the infection.
Immunoblots
Cell lysates for immunoblot were prepared as previously
described [40]. Proteins were separated by SDS-poly-
acrylamide gel electrophoresis and immunoblots were
probed with anti-SA114F rotavirus polyclonal antiserum
that recognizes structural proteins VP2 and VP6, anti-
GAPDH (Ambion), or anti-NSP2 (kindly provided by MEstes, Baylor College of Medicine) antibodies. Proteins
that reacted with antibody were visualized by chemilu-
minescence using the Pierce ECL kit.
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